观点网讯：10月20日，中国中药集团私有化建议失效。

中国中药宣布，国药集团共裕按每股4.6港元将公司私有化的先决条件仍未得到满足。因此，建议于10月18日失效，股份在联交所的上市地位将不会撤销。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.